Merck & Co Inc
NYSE: MRK
$115.88
-$1.30 (-1.1%)
Real Time Data Delayed 15 Min.
MRK Articles
The stock market was pounded on Friday, making for a very bad week and a rough start for January. Still, not all is lost. A few stocks managed to avoid the carnage. Despite a drop of 318 points in...
Published:
Last Updated:
ThinkstockWednesday was yet another mixed day in the stock market, one where the Dow Jones Industrial Average was in the red and the S&P 500 Index and NASDAQ were positive for most of the day....
Published:
Jon OggThe markets had only a small employment report from the Conference Board to consider on Monday, as well as a surprising government budget surplus, to drive stocks today. Unfortunately, Goldman...
Published:
Jon OggWe are now well past the end of 2013, and many strategists have mixed targets for the stock and bond markets in 2014. The last year brought gains of 26.5% in the Dow Jones Industrial Average...
Published:
With a new year comes new expectations. 24/7 Wall St. has generated a bullish and bearish scenario for 2014 in each stock of the Dow, including Pfizer and rival Merck & Co.
Published:
courtesy of VerizonThe short interest data for the end of November is out, and the results are somewhat surprising when it comes to the top high-yield safe dividends out there. Some of the changes...
Published:
ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of the Dow, which is simply made up of the 10 Dow Jones Industrial Average (DJIA) components...
Published:
ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most companies paying dividends in nearly two decades....
Published:
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that...
Published:
ThinkstockSkin cancer treatments remain elusive. While some drugs are on the market for advanced-stage treatment, the most common and longest method of initial treatment still involves the doctor...
Published:
While the past two years were all about getting the house back in order, the UBS equity strategy team thinks 2014 is all about earnings growth. That should be sweet music to the ears of investors....
Published:
Last Updated:
Jon OggWe have now seen the short interest reports from the October 31 settlement date and have compared them to the October 15 settlement date. This is important because it reflects the opinions and...
Published:
ThinkstockThe unemployment situation in the United States looked relatively good through the first half of the year. The jobless rate dropped to 7.3% in October from 7.9%% at the beginning of the...
Published:
ThinkstockOctober’s jobs report showed a gain of 204,000 people to nonfarm payrolls. That is a pace of 1.5 million job additions for 2013. Many earlier months have been better. The Bureau of Labor...
Published:
Jon OggInvestors are having to deal with seeing stocks hit new highs almost daily now. With a temporary deal in Washington, D.C., and with earnings coming on strong, investors are caught trying to...
Published: